The negative effects of HRT that appeared in those with a history of breast cancer and in BRCA1 carriers in our study may be attributed to excessive baseline levels of inflammation and oxidative stress associated with cancer treatment [34] and BRCA1 deficiency—BRCA1 protects against neuronal damage through the activation of the Antioxidant Response Element signaling pathway, as it interacts with the nuclear factor (erythroid-derived 2)-like 2 (NRF2) through the BRCA1 C-terminal (BRCT) domain [6]. This evidence concerns the gene NFE2L2 and breast cancer.